Takeda's academic alliance aims to accelerate nanoparticle vaccine research
This article was originally published in Scrip
Takeda's support of a new joint research chair at Osaka University in Japan is designed to progress research into vaccines containing novel nanoparticle adjuvants, which hold out the promise of improved safety and immunogenic response.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.